BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 11, 2003
View Archived Issues
Business highlights at Regeneron
Read More
Scancell and Celltech collaborate on antibody therapeutics to Lewis(y/b)
Read More
Levitra is effective in men of diverse ethnic origin
Read More
New NHE-3 inhibitors and their use covered by Merck KGaA patent
Read More
Merck KGaA presents novel PDE7 inhibitors
Read More
New PARP inhibitors in early development at Fujisawa
Read More
Dual 5-HT/noradrenaline uptake inhibitors and their use described by Lundbeck
Read More
MMP inhibitors, their preparation and biological evaluation reported by Sumitomo
Read More
Micrologix claims new L-nucleoside derivatives with anti-HBV activity
Read More
EP2 receptor agonist CP-533536 offers a therapeutic alternative for bone fractures and defects
Read More
E.U. orphan drug status awarded to Fidelin for adrenal insufficiency
Read More
Pivotal phase III trial for Cellegesic makes solid progress
Read More
CART-2 trial of AGI-1067 completes enrollment
Read More
Lapdap approved by U.K. agency for treatment of P. falciparum malaria
Read More
EFECT studies new breast cancer population for Faslodex
Read More
Quark Biotech and Fujisawa extend stroke collaboration
Read More
ACP-103 completes phase I testing
Read More
FDA panel recommends Onyx for treatment of arteriovenous malformations
Read More
Phase III study for RSD-1235 in atrial fibrillation commences dosing
Read More
Combination of NF-kB inhibitors and DNA-damaging agents for improving therapeutic outcome
Read More